Sangui Biotech International, Inc.

Equities

SBH

US80105B1017

Biotechnology & Medical Research

End-of-day quote Hanseatische Wertpapierboerse Hamburg Other stock markets 07:00:00 2024-03-19 pm EDT			5-day change	1st Jan Change
0.002 ^EUR	-20.00%		-.--%	-33.33%

Feb. 15	Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
2023	Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	CI

Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023

November 14, 2023

Sangui Biotech International, Inc. reported earnings results for the first quarter ended September 30, 2023. For the first quarter, the company reported revenue was USD 0.020723 million compared to USD 0.041029 million a year ago. Net income was USD 0.008099 million compared to USD 0.023232 million a year ago.

Latest news about Sangui Biotech International, Inc.

Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 14	CI
Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-12	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-07	CI
Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-10	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	22-09-28	CI
Sangui Biotech International, Inc. Auditor Raises 'Going Concern' Doubt	22-09-27	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-05-16	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	22-02-11	CI
Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021	21-11-12	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Full Year Ended June 30, 2021	21-09-28	CI
Sangui Biotech International, Inc. Auditor Raises 'Going Concern' Doubt	21-09-27	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2021	21-05-07	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2020	21-02-09	CI
Sangui Biotech International, Inc. Announces Earnings Results for the First Quarter Ended September 30, 2020	20-11-13	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Full Year Ended June 30, 2020	20-09-30	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2020	20-05-14	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2019	20-02-13	CI
Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2019	19-11-13	CI
Sangui Biotech International, Inc. Reports Sales Results for the Fiscal Year of 2019	19-10-09	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Full Year Ended June 30, 2019	19-10-08	CI
Sangui Biotech International Inc. Announces Earnings Results for the Third Quarter and Nine Months Fiscal Year 2019	19-05-14	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2019	19-05-13	CI
Sangui Biotech International, Inc. Announces Earnings Results for the Second Quarter and First Half of 2019	19-02-14	CI
Sangui Biotech International, Inc. Announces Earnings Results for the First Quarter Ended September 30, 2018	18-11-15	CI

Chart Sangui Biotech International, Inc.

Duration

Period

Chart Sangui Biotech International, Inc.

More charts

Company Profile

Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SANGUI BIOTECH INTERNATIONAL, INC.	-33.33%	448K
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research